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Genetic modulation of oxytocin sensitivity: a pharmacogenetic
approach
FS Chen1,2,8, R Kumsta3,8, F Dvorak4,5, G Domes1,7, OS Yim6, RP Ebstein6 and M Heinrichs1,7
Intranasal administration of the neuropeptide oxytocin has been shown to inﬂuence a range of complex social cognitions and
social behaviors, and it holds therapeutic potential for the treatment of mental disorders characterized by social functioning deﬁcits
such as autism, social phobia and borderline personality disorder. However, considerable variability exists in individual responses to
oxytocin administration. Here, we undertook a study to investigate the role of genetic variation in sensitivity to exogenous oxytocin
using a socioemotional task. In a randomized, double-blind, placebo-controlled experiment with a repeated-measures (crossover)
design, we assessed the performance of 203 men on an emotion recognition task under oxytocin and placebo. We took a
haplotype-based approach to investigate the association between oxytocin receptor gene variation and oxytocin sensitivity. We
identiﬁed a six-marker haplotype block spanning the promoter region and intron 3 that was signiﬁcantly associated with our
measure of oxytocin sensitivity. Speciﬁcally, the TTCGGG haplotype comprising single-nucleotide polymorphisms rs237917–
rs2268498–rs4564970–rs237897–rs2268495–rs53576 is associated with increased emotion recognition performance under oxytocin
versus placebo, and the CCGAGA haplotype with the opposite pattern. These results on the genetic modulation of sensitivity to
oxytocin document a signiﬁcant source of individual differences with implications for personalized treatment approaches using
oxytocin administration.
Translational Psychiatry (2015) 5, e664; doi:10.1038/tp.2015.163; published online 27 October 2015
INTRODUCTION
The neuropeptide oxytocin has a key role in the regulation of
complex social cognition and behaviors, including mammalian
pair bonding, maternal behavior, recognition of conspeciﬁcs and
responses to social stress.1,2 Human studies have documented a
number of effects of intranasally administered oxytocin on social
behavior and social cognition.3–5 For instance, a single dose of
intranasal oxytocin increases trusting behavior,6 attention to the
eye region of faces7,8 and the accuracy with which individuals
interpret emotional information from eyes.9 Oxytocin also reduces
subjective and physiological responses to social stress and
enhances the stress-buffering effect of social support.10 Neuro-
imaging studies have shown that one of the mechanisms through
which oxytocin inﬂuences social cognition is by attenuating
amygdala responses to social stimuli such as emotional faces.11–14
There has also been considerable interest in the therapeutic
potential of oxytocin for the treatment of mental disorders
characterized by social functioning deﬁcits such as autism,15–19
social phobia20,21 and borderline personality disorder.22 Whereas
the results of virtually all of these studies suggest that oxytocin
has the potential to improve social cognition and social behavior
in healthy individuals and patient populations, there is consider-
able variability in individual responsiveness to oxytocin adminis-
tration, with some individuals showing strong behavioral effects in
response to intranasal oxytocin and others seeming to show
minimal or no effects.3 These ﬁndings suggest that oxytocin
administration may interact with pre-existing interindividual
variation that inﬂuences the efﬁcacy of oxytocin signaling in the
central nervous system. Speciﬁcally, genetic variation inﬂuencing
the number, distribution or functioning of oxytocin receptors may
inﬂuence oxytocin sensitivity. Research investigating the genetic
modulation of sensitivity to oxytocin administration has implica-
tions not only for basic research but also implications for clinicians
who would like to predict which patients may or may not beneﬁt
from oxytocin administration, and in general may help to reﬁne
personalized oxytocin-based therapies for mental disorders.
Initial studies using a molecular genetic approach suggest that
common variations in the human oxytocin system are relevant for
social behavior.23 Speciﬁcally, variation in the human oxytocin
receptor gene (OXTR) has been associated in some studies to
susceptibility for mental disorders characterized by social
deﬁcits such as autism spectrum disorder24 (although the speciﬁc
single-nucleotide polymorphism(s) (SNP(s)) and allele(s) linked
to greater susceptibility have varied depending on ethnicity
and other sample characteristics).25–28 In addition, variants of
OXTR have been linked to individual differences in psychological
and physiological response patterns to stress and social
information,29,30 as well as to differences in general socio-
behavioral phenotypes. These include prosocial behavior,31
empathy,32 trust33 and sensitive parenting.34 Structural and
functional imaging studies have shown associations between
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OXTR SNPs and morphometric alterations as well as differences in
activity of neural circuits involved in the processing of social
information and negative affect. These imaging studies suggest
that genetic variation of OXTR inﬂuences limbic circuitry involving
the amygdala, the hypothalamus and the cingulate gyrus.35–38
Given the associations that have been documented between
OXTR variability and social behavior, and given that oxytocin
exerts its function via the oxytocin receptor, OXTR variability is a
prime candidate for explaining individual differences in response
to exogenous oxytocin administration. To test this possibility, we
conducted a randomized, double-blind, placebo-controlled experi-
ment with a repeated-measures (crossover) design. We assessed
each participant’s performance on an emotion recognition task
previously shown to be sensitive to oxytocin administration,39
both under oxytocin and placebo. This within-subject design
provides a measure of each individual’s socioemotional sensitivity
to oxytocin administration.
Whereas most association studies so far have focused on single
SNPs, we investigated 23 SNPs across the OXTR gene region and
took a haplotype-based approach in our analyses. In addition to
allowing us to capture more genetic information than single SNP
analysis,40 the haplotype approach—which by deﬁnition jointly
tests multiple SNPs for association—allows us to avoid the
conundrum of multiple testing, which can result in false-positive
results. As has been noted by other researchers,41 divergent
results between studies may sometimes have arisen from
unrecognized haplotype effects because these studies were
limited to investigation of individual SNPs. In addition, question-
able results may arise from disregarding linkage disequilibrium
(LD) of the tested polymorphism, an effect preventable by
haplotype analysis (see Binder et al.42 for further discussion of
haplotype analysis).
MATERIALS AND METHODS
Subjects
We tested 207 men between 19 and 30 years of age (M= 23.5 years,
s.d. = 2.7 years) of Central European descent from the student population
of the University of Freiburg, Germany, who were recruited through
on-campus advertisements. The sample size was determined on the basis
of recent research demonstrating effects of common variants of OXTR on
behavior.43–47 Participants were pre-screened to ensure that they were
ﬂuent in German, were not suffering from mental or physical illnesses and
were not taking drugs or medication. Students studying psychology were
excluded from our sample. All participants gave written, informed consent
before the start of the ﬁrst experimental session and received a total of 40
Euro for participation in the two sessions. The study was approved by the
institutional review board of the University of Freiburg.
Procedure
Each participant was tested twice, with a 1-week gap between testing
sessions. All sessions took place in the afternoon and lasted ~ 2 h.
Participants were tested in a laboratory in groups of 12–16, with each
participant seated at a computer in an individual cubicle. Dividing walls
prevented visual contact between the participants, and participants were
instructed not to speak to each other during the testing sessions.
Substance administration. After completing a questionnaire to assess
baseline mood (the Multidimensional Mood Questionnaire48), participants
received either oxytocin (Syntocinon-Spray, Novartis, Basel, Switzerland) or
placebo intranasally in a randomized, double-blind, crossover design. The
placebo included all of the same ingredients as the oxytocin spray except
for the neuropeptide. Under the supervision of the experimenter,
participants self-administered 24 IU of the substance (three puffs into
each nostril in alternating order).10 After a loading period of 45min, the
participants completed a second Multidimensional Mood Questionnaire to
assess their mood.
Emotion recognition task. Participants subsequently completed a task
based closely on one used by Lischke et al.39 to assess their ability to
recognize emotions from dynamic facial expressions. Previous research
suggests that this task is sensitive to oxytocin administration: participants
who received oxytocin identiﬁed emotions more quickly and at a lower
intensity level than participants who received placebo.39 In each trial, a
photo of an individual displaying a neutral expression gradually morphed
into a photo of the same individual displaying a happy, angry, fearful or
sad expression. The participant’s task was to press a button when he
recognized the emotion being displayed. Participants were instructed to
respond as quickly and accurately as possible. As soon as the participant
responded, the morphing procedure stopped and the image was replaced
by a prompt asking the participant to indicate which of the four emotions
he had detected (see Supplementary Information for details).
Non-social control task. To test whether any observed effects would be
speciﬁc to social stimuli, participants also completed a control task for the
recognition of non-social stimuli (cars) after the emotion recognition task.
Using Winmorph 3.01 (http://www.debugmode.com/winmorph/), gray-
scale images of a common car model (a small hatchback) were morphed
into images of target cars (four exemplars each of the car types: Smart car,
box truck, pickup truck and VW Beetle). As in the emotion recognition task,
participants were instructed to press a button as soon as they recognized
the target car type. Before the 16 test trials, participants completed four
practice trials. The test trials appeared in one of two pseudorandomized
testing orders. For each trial, reaction time and accuracy were recorded.
During the second session, a saliva sample was collected from each
participant (Oragene 500-OG kit, DNA Genotek, Ottawa, Ontario, Canada)
for genotyping. Participants were also asked at the end of the second
session whether they thought they had received oxytocin or placebo in
that session.
SNP selection and genotyping
The goal of this study was to associate variation of OXTR with oxytocin
sensitivity. In order to capture the maximum amount of genetic
information, we chose 23 SNPs across the OXTR gene for subsequent
haplotype-based analyses. Sixteen SNPs were selected on the basis of an
association study with SNP coverage across OXTR.26 Seven additional SNPs
were selected; rs53576 was included because a large number of studies
have shown signiﬁcant associations between this SNP and sociobehavioral
phenotypes.23 SNP rs2268498, located in the promoter region, was
included because of its presumed functional signiﬁcance.49 In order to
increase coverage of the 5′ region, a likely region of regulatory activity,
four additional SNPs compatible with the multiplex assay were selected
from SNP databases. This selection procedure is a standard a priori
approach to haplotype testing, where not a single SNP but rather SNPs
across a gene region and their pattern of LD are taken into account.
DNA was extracted from saliva in Oragene collection vials by desalting
procedure following the manufacturer’s protocol. SNP genotyping was
performed on the Sequenom MassArray platform using iPLEX Gold
chemistry (Sequenom, San Diego, CA, USA). Primers and multiplexes were
designed using the Sequenom's MassArray Assay Design v4.0 Software.
Multiplex PCR was performed using iPlex Gold reagents in 5-μl reactions as
recommended by the manufacturer. Three hundred eighty-four-well PCR
plates were used for PCR ampliﬁcation on a GeneAmp 9700 thermocycler
(Applied Biosystems, Waltham, MA, USA), and the products were spotted
onto 384-well SpectroCHIP arrays (Sequenom) using the Nanodispenser
RS1000 (Sequenom). Spotted SpectroCHIPs were then ﬁred in a MassArray
Analyzer 4 Matrix-Assisted Laser Desorption/Ionization-Time Of Flight mass
spectrometer. Procedures used were as in the manufacturer's protocol.
Data analyses were performed on Sequenom's Typer Software Module,
and ambiguous genotype calls were manually conﬁrmed. Out of the 23
genotyped SNPs (see Supplementary Table 1), 7 were not in Hardy–
Weinberg equilibrium and 2 SNPs had a minor allele frequency below 5%.
Genotyping failed for SNP rs237894. Therefore, 13 SNPs were included in
the association test (see Results).
Statistics
We analyze data from all participants (N= 203) who completed the
emotion recognition task in both sessions and for whom genotyping was
successful. Accuracy of emotion recognition and reaction time were
recorded for each trial. Accuracy was near ceiling (M= 88%, s.d. = 9%) and
is thus not considered in the following analyses. Reaction times were
averaged across all accurate trials.
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Preliminary analyses showed a main effect of time, indicating that
reaction times improved between the ﬁrst and second sessions for all
groups. Therefore, reaction times were standardized (z-transformed)
separately for each session (1 and 2). In order to obtain a measure for
oxytocin sensitivity, a difference score was calculated (subtracting
standardized reaction times under oxytocin from standardized reaction
times under placebo).
Haplotype analyses were performed with version 3.1.6 of the program
UNPHASED.50 Associations between haplotypes and the quantitative trait
oxytocin sensitivity were tested with the individual haplotype test
implemented in UNPHASED. This option gives individual tests for each
haplotype in turn, and tests for a difference between a haplotype and all
the others pooled together. The outcome variable was our measure for
oxytocin sensitivity, that is, the difference in reaction time between
oxytocin and placebo. Using a sliding window approach, seven to two
marker haplotypes were tested. Only haplotypes with a frequency of
42.5% were analyzed. In order to correct for multiple testing, the
permutation test option as provided in UNPHASED was used. Permutation
test correction was performed using 1000 iterations (random permuta-
tions) and was applied to correction of global P-values (the P-value
generated by UNPHASED as an overall test of each block of haplotypes).
In order to conﬁrm the results obtained using UNPHASED, which used
the difference score as an outcome measure, a General Linear Model for
repeated measures, with reaction time under oxytocin and placebo as
repeated variables, haplotype as the between-subject factor, and order of
substance administration as a covariate was computed (SPSS Version 20,
IBM, Armonk, NY, USA). Assumptions of normality, equality of variance in
the groups being compared, and sphericity were checked and met by the
data. In all analyses, two-tailed P-values are reported.
RESULTS
The assayed SNPs, their location along the OXTR genomic region
and their relationship to the exon/intron boundaries of the gene
are shown in the upper part of Figure 1. The lower part shows the
LD map of the genotyped SNPs as depicted by Haploview.
Haplotype analyses revealed signiﬁcant associations between
oxytocin sensitivity and haplotypes of marker sizes six to two
(Table 1). A more detailed analysis of the six-marker block showed
that two haplotypes differed signiﬁcantly from the remaining
ones: CCGAGA and TTCGGG (with frequencies of 7.1% and 28.3%,
respectively; see Table 2).
In order to specify the direction of effects, we compared
oxytocin sensitivity scores (based on the emotion recognition
speed under oxytocin versus placebo; see Materials and methods)
among three groups: carriers of the two signiﬁcant haplotype
groups (TTCGGG and CCGAGA) and the group comprising the
remaining haplotype combinations (Other group). As shown in
Figure 2, the two signiﬁcant six-marker haplotypes showed
opposing effects. Both carriers of the TTCGGG haplotype and
carriers of the CCGAGA haplotype showed differential sensitivity
to oxytocin relative to the Other group. Speciﬁcally, carriers of the
TTCGGG haplotype recognized emotions more quickly and at a
lower intensity level under oxytocin compared with placebo;
CCGAGA carriers showed the opposite pattern. When all genotype
groups were combined, there was no main effect of oxytocin on
emotion recognition speed.
Figure 1. Upper panel a shows the location of the single-nucleotide polymorphisms (SNPs) along the OXTR gene. Lower panel b shows the
linkage disequilibrium map of the OXTR SNPs genotyped in our sample produced by Haploview.
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The results obtained using UNPHASED, which used the
difference score as the outcome measure, were conﬁrmed with
a general linear model for repeated measures, with reaction time
under oxytocin and placebo as repeated variables, six-marker
haplotype as the between-subject factor and order of substance
administration as a covariate (haplotype by substance interaction:
F2,186 = 5.80; P= 0.004).
With regard to the blocks of smaller window sizes, with very
few exceptions, the same allelic combinations (comprising subsets
of the alleles in the six-marker haplotypes) drove the
signiﬁcant associations (see Supplementary Table 2; detailed
results for the other haplotype windows can be found in
Supplementary Table 3).
There is one additional three-marker haplotype in intron 3
comprising SNPs rs2254298–rs2268494–rs9840864 showing
signiﬁcant results (Figure 3). As shown in Table 3, the A-allele of
rs2254298, which also shows a nominally signiﬁcant association on
the single SNP level, falls exclusively on the signiﬁcant haplotype.
Furthermore, the six SNPs that make up the signiﬁcant six-marker
haplotype and additionally rs2254298 were signiﬁcantly associated
with sensitivity to oxytocin on their own (see bottom of Table 1),
with rs237897 surviving Bonferroni correction for 13 tested SNPs.
Non-social control condition and additional analyses
General Linear Model analyses showed no haplotype by substance
interactions (F2,180 = 1.52; P= 0.22) under the non-social control
condition, which used cars that morphed from a ‘neutral’ model
into one of four other models as stimuli, supporting the view that
the effects of oxytocin are speciﬁc for social stimuli.
Finally, as a group, participants were not able to tell whether
they had received oxytocin or placebo (the accuracy rate of 53%
did not differ from the chance level of 50%, Z= 0.85, P= 0.39).
Table 1. Haplotypes associated with oxytocin sensitivity
Black bars indicate those haplotype blocks that remained signiﬁcant
following the permutation test with 1000 iterations. Adjusted P-values are
shown for blocks of sizes 2–6, and unadjusted P-values are indicated for
single SNPs.
Table 2. Detailed analysis of 6-marker haplotype block
rs237917–rs2268498–rs4564970–rs237897–rs2268495–rs53576
Haplotype Frequency X2 P
Likelihood ratio X2 = 14.78, df = 6,
global P-value = 0.022 (0.048)
C-C-G-A-G-A 0.283 7.483 0.006
C-T-G-G-G-G 0.218 0.127 0.720
T-T-G-G-A-G 0.156 3.113 0.078
C-C-G-A-G-G 0.074 0.083 0.774
T-T-C-G-G-G 0.071 6.681 0.010
C-C-G-G-A-G 0.066 0.877 0.349
T-T-G-A-G-A 0.049 0.176 0.675
Abbreviation: df, degrees of freedom. Global P-value and permutation-
corrected P-value (shown in brackets) for the six-marker haplotype
window. Individual tests for each haplotype showed that two haplotypes
(CCGAGA and TTCGGG) differed signiﬁcantly (indicated in bold) from the
remaining haplotypes.
Figure 2. Graph shows relative oxytocin sensitivity across groups for
the six-marker haplotype block rs237917–rs2268498–rs4564970–
rs237897–rs2268495–rs53576. Oxytocin sensitivity was indexed in
terms of emotion recognition speed under oxytocin compared with
placebo. Higher values indicate faster reaction times under oxytocin.
Figure 3. Graph shows relative oxytocin sensitivity across groups for
the three-marker haplotype block rs2254298–rs2268494–rs9840864.
Oxytocin sensitivity was indexed in terms of emotion recognition
speed under oxytocin compared with placebo. Higher values
indicate faster reaction times under oxytocin.
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Participants’ mood was not affected by receiving oxytocin versus
placebo (that is, changes in Multidimensional Mood Questionnaire
scores from pre- to post-spray application did not differ by the
substance group, all P40.20).
DISCUSSION
There are several lines of evidence implicating the central oxytocin
system in the etiology of mental disorders characterized by social
deﬁcits. This is supported by genetic studies linking SNPs and
haplotypes of OXTR to individual differences in social behavior.
Furthermore, several of these SNPs have been associated with
structural and functional changes in human brain regions involved
in a regulatory circuit of socioemotional information processing.
The discovery that neuropeptides can be non-invasively delivered
to the brain in humans has raised considerable interest in the
therapeutic potential of oxytocin for the treatment of disorders
characterized by social functioning deﬁcits.3,4
Here, we investigated whether sensitivity to oxytocin adminis-
tration is inﬂuenced by genetic variation of OXTR. We identiﬁed a
six-marker haplotype block spanning the promoter region and
intron 3 that was signiﬁcantly associated with our measure of
oxytocin sensitivity, emotion recognition performance under
oxytocin versus placebo. Speciﬁcally, we identiﬁed two haplotypes
that were differentially associated with oxytocin sensitivity: the
TTCGGG haplotype comprising SNPs rs237917–rs2268498–
rs4564970–rs237897–rs2268495–rs53576 is associated with
increased emotion recognition performance under oxytocin
versus placebo, and the CCGAGA haplotype with the opposite
pattern. It is of note that the A allele of rs53576, previously
associated with phenotypes including reduced empathy, lower
trust, reduced sensitivity to social support in the context of stress
and less sensitive parenting, falls almost exclusively on the
CCGAGA haplotype. In the present study, this haplotype was
associated with decreased emotion recognition speed under
oxytocin compared with placebo.
The functional consequences associated with this haplotype are
currently unknown. Speculatively, it is possible that previously
reported ﬁndings in the literature involving rs53576 are function-
ally explained by LD with the SNPs located in the regulatory
region of OXTR, possibly inﬂuencing transcriptional efﬁciency.
There is tentative evidence that promoter SNP rs2268498,
associated with negative emotionality49 and moral judgments,51
inﬂuences OXTR gene regulation (referred to in Montag et al.49 as
unpublished data). Detailed functional in vitro characterization of
OXTR promoter SNPs, including rs2268498, is warranted.
Although a number of other studies have used single SNP
approaches to examine the effect of oxytocin intranasal admin-
istration on social cognition, we are not aware of the speciﬁc use
of haplotype analysis in experiments that involve intranasal
oxytocin administration. There are studies that have used
haplotype analysis to examine association between the oxytocin
receptor, behavior and psychopathology. For instance, in a study
by Lerer et al.,26 several OXTR haplotypes were associated with
autism. Signiﬁcant ﬁndings emerged for haplotypes comprising
SNPs in intron 1 and the untranslated part of exon 4. Of note,
associations were shown with haplotypes of several sizes
including SNPs rs237897 and/or rs2254298. The ﬁrst SNP is part
of our six-marker haplotype, and rs2254298 is tagging the three-
marker haplotype identiﬁed in the present study. Another
haplotype-based analysis identiﬁed an association between social
cognition and a haplotype consisting of rs11131149 and
rs2254298.52 A third study showed that a haplotype comprising
SNPs rs9840864 and rs2268494—the latter being part of the
signiﬁcant three-marker block in our study—was associated with
anger and retaliation after betrayal.47 This shows some conver-
gence between studies; however, as our study had a more
extensive coverage of the 5´ region of the gene, and the other
studies did not or only partially include the SNPs of our six-marker
haplotype, the results cannot be directly compared.
Our results suggest that oxytocin administration facilitates
emotion recognition in some individuals more than others. The
fact that no main effect of oxytocin was observed in this study
when all genotype groups were combined highlights the critical
inﬂuence of individual difference factors in oxytocin administra-
tion effects. The ability to recognize the emotions of others is a
building block for empathy and has been associated with
prosocial behavior.53 Impairments in the ability to recognize
emotions are also characteristic of several mental disorders
involving social deﬁcits, including autism54 and borderline
personality disorder.55 Preliminary evidence suggests that oxyto-
cin may indeed alleviate impairments in emotion recognition in
some clinical samples.8,18,56 By identifying particular individuals
who respond to oxytocin administration more strongly than
others in the context of an emotion recognition task, the current
study provides a ﬁrst step toward predicting which individuals are
likely to proﬁt from oxytocin-based treatments intended to
alleviate impairments in socioemotional functioning.
We chose the emotion recognition task in our study based on
the fact that it has been shown to be sensitive to oxytocin
administration.39 Furthermore, because it involves dynamic
stimuli, this task arguably has more ecological validity than tasks
involving static photos of faces. However, future research will be
necessary to test the generalizability of our reported ﬁndings to
other emotion recognition tasks, to other tasks relevant for
empathy and prosocial behavior and to other types of settings
and contexts.
Because previous results have suggested sex differences in
associations between OXTR genotype and phenotype57 as well as
in responses to intranasal oxytocin administration,11,58 we decided
to limit our current study to male participants. Follow-up studies
testing women are necessary to examine the generalizability of
our ﬁndings and are expected to be particularly informative, given
the potential for sex differences in this domain. As with all genetic
association studies, our ﬁndings should be replicated in an
independent sample and with a larger sample size to establish the
robustness of the effects we observed. Given that different
directions of genotype–phenotype associations have been
observed in different ethnicities,25,28 future work should also test
the effects reported here in other ethnic groups. Furthermore, the
distribution of these haplotypes in samples with impairments in
socioemotional functioning should be documented in future
research. This information on haplotype distributions may help to
elucidate some of the potential sources of these socioemotional
impairments and may also help identify speciﬁc samples for which
oxytocin-based therapies are more or less likely to be effective.
Table 3. Detailed analysis of 3-marker haplotype block
rs2254298–rs2268494–rs9840864
Haplotype Frequency X2 P
Likelihood ratio X2 = 8.23, df = 3, global
P-value = 0.042 (0.046)
G-T-G 0.771 0.336 0.562
A-T-C 0.093 6.269 0.012
G-T-C 0.070 2.386 0.122
G-A-C 0.060 0.151 0.697
Abbreviation: df, degrees of freedom. Global P-value and permutation-
corrected P-value (shown in brackets) for the three-marker haplotype
window that falls outside the region delineated by the six-marker window
shown above. The ATC haplotype, tagged by the A allele of rs2254298,
differs signiﬁcantly (indicated in bold) from the remaining haplotypes.
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It is also likely that epigenetic modiﬁcations of OXTR inﬂuence
oxytocin sensitivity.59 Functional studies have shown that
differential methylation of a CpG island in the OXTR promoter
seems to be functionally important for OXTR expression,60 and
differences in the degree of methylation have been observed in
childhood disorders characterized by impairments in social
cognition, including autism61 and conduct problems concurrent
with callous-unemotional traits.62
In addition to OXTR, other factors involved in the oxytocin
pathway might inﬂuence oxytocin sensitivity. These include the
gene for oxytocin (OXT; coding for the precursor protein oxytocin-
neurophysin-I), the gene encoding the enzyme that metabolizes
oxytocin, oxytocinase (human leucyl/cystinylaminopeptidase;
LNPEP) as well as CD38, a key mediator of oxytocin brain
release.63,64 In the long term, future studies involving larger sample
sizes may help to elucidate the role of these other genes, along
with potential gene–gene interactions in oxytocin sensitivity.
The current study, which demonstrates genetic modulation of
sensitivity to oxytocin administration, identiﬁes one speciﬁc and
systematic source of individual differences in response to oxytocin
administration. The identiﬁcation of this new haplotype block
conferring differences in oxytocin-induced socioemotional behav-
ior will not only help advance a basic scientiﬁc understanding of
the human oxytocin system but may also improve the prediction
of clinical outcomes of novel therapy approaches using oxytocin.
More speciﬁcally, these results may help to bridge the insights
from a pharmacogenetic approach to psychobiological therapy
combining oxytocin administration and psychotherapy4,65,66 for
genetically targeted subgroups of patients with social deﬁcits
across diagnostic categories of mental disorders (for example,
autism spectrum disorder, social anxiety disorder and borderline
personality disorder). More such personalized treatment
strategies67,68 are necessary to help fulﬁll the immense promise
of translational success of oxytocin-based therapies.
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